MEK Inhibitors

What is a MEK inhibitor? Also known as Trametinib

Trametinib (Mekinist®) is a type of drug called a MEK inhibitor. It works by targeting a certain protein in cancer cells and stopping them from being able to grow and divide.

Who is Trametinib available for?

Trametinib is specifically available for women with low grade serous ovarian cancer (LGSOC) which has either returned or progressed, and who have had had at least one line of platinum chemotherapy. Access varies depending on where in the UK you live, so speak to your cancer team to find out more.

How is trametinib given?

Trametinib is given as tablets that you take every day at home.

Side effects

Side effects of trametinib can include:
rash
low red blood cells
increased blood pressure
diarrhoea
feeling sick
extreme tiredness (fatigue)

You will have regular blood tests to keep track of your blood levels and the functioning of your liver and kidneys. It’s very important to keep your cancer team updated with any side effects you’re having so they can advise you. They will let you know how to contact them if you’re experiencing any of the above.